Little Miracles makes U.S. debut
LOS ANGELES — Little Miracles, an organic energy brand based in the United Kingdom, on Wednesday announced availability of its collection of teas and juices in the United States. The beverages are designed for on-the-go women who are looking for an energizing boost, the company said.
"We've been listening to the market both here and abroad, and are carving out a new category of all occasion, functional beverages," said Laura Sauls, U.S. marketing manager. "We're pleased to bring Little Miracles beautiful tea blends to the American marketplace, as it is the evolution of what health-conscious consumers want in a beverage they can drink every day — organic ingredients you can trust, the magic of superfoods and tasty, on-the-go refreshment."
Little Miracles are available in four organic blends: Green Tea & Pomegranate, White Tea & Cherry, Black Tea & Peach and Lemongrass Tea, Orange Juice & Ginger. The beverages are now available at more than 1,200 retailers across the country, including Sprouts, SuperValu and Albertsons Southern California. Consumers also can order online at Amazon.
General Mills announces new Cheerios variety
MINNEAPOLIS — Cheerios, a brand from General Mills, announced the launch of Cheerios Protein. The company is billing the product as a "smart solution" that provides a boost of energy for hectic mornings.
"Parents are looking for breakfast options that not only provide long-lasting energy, but also something their entire family will enjoy at times that are right for them," said Matt McQuinn, senior marketing manager of Big G Cereal New Products. "Cheerios Protein offers the benefits that go along with starting the day with 11 g of protein and the great taste of Cheerios that kids and parents already know and love."
The Cheerios Protein combines toasted cereal with granola clusters in two varieties: Oats & Honey and Cinnamon Almond. Consumers can find the new cereal at retailers nationwide in 14.1-oz. boxes.
Actavis files ANDA for diabetes remedy Onglyza
DUBLIN — Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.
Actavis’ ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb’s Onglyza, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
AstraZeneca AB filed suit against Actavis on May 23, 2014 in the U.S. District Court for the District of Delaware, seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent No. 7,951,400. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis’ ANDA until Jan. 31, 2017, or final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.
Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Onglyza and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.
For the 12 months ending Feb. 28, 2014, Onglyza had total U.S. sales of approximately $532 million, according to IMS Health data.